Participant flow

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma · Source last updated 2026-03-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Carfilzomib (intravenous (IV), Days 1, 2, 8, 9, 15, and 16 of the 28-day cycle); Revlimid (by mouth (PO), Days 1-21 of the 28-day cycle; exception: not given on cycle 1 day 1); and Dexamethasone (PO or IV, Days 1, 2, 8, 9, 15, 16, 22, and 23 of the 28-day cycle; exception: not given on cycle 1 day 1) Carfilzomib intravenous (IV) 20-36 mg/m\^2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity. Revlimid by mouth (PO) 25 mg/day, days 1-21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.

   id

   FG000

   title

   All Participants

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         55

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         54

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Participants Enrolled

2. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Discontinued drug/Off Study

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         54

      type

      STARTED

   2. achievements

      1. comment

         2 participants discontinued drug administration early because of adverse events, thus 1 was taken off study and 1 proceeded to maintenance.

         group Id

         FG000

         num Subjects

         53

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Drug Administration

3. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Discontinued maintenance therapy/experienced adverse events and withdrew consent

   2. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Discontinued maintenance therapy/experienced adverse events

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         53

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         50

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      NOT COMPLETED

   title

   Initiated Maintenance Therapy

4. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         50

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         30

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         20

      type

      NOT COMPLETED

   title

   Completed Maintenance Therapy

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice